iBio (NASDAQ:IBIO) Stock Rating Upgraded by Wall Street Zen

iBio (NASDAQ:IBIO) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other brokerages have also issued reports on IBIO. Lifesci Capital raised iBio to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, iBio currently has an average rating of “Buy”.

iBio Stock Down 8.1%

IBIO stock opened at $2.82 on Friday. iBio has a 52 week low of $0.56 and a 52 week high of $6.89. The stock’s 50-day moving average is $2.25. The stock has a market capitalization of $97.41 million, a PE ratio of -2.82 and a beta of 1.26.

iBio (NASDAQ:IBIO) last issued its quarterly earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.